Author

A. M. Carter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 4 Assay:proteomics· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

H. Chen· 4 shared J. A. Bibb· 4 shared R. Telange· 4 shared S. Reddy· 4 shared C. Tan· 3 shared M. S. Mukhtar· 3 shared N. Kumar· 3 shared R. Jaskula-Sztul· 3 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

H. Chen

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid Carcinoma

P. Gupta, B. Herring, N. Kumar, R. Telange, S. Garcia-Buntley, T. Caceres, S. Colantonio, F. Williams, P. Kurup, A. M. Carter, D. Lin, H. Chen, B. Rose, R. Jaskula-Sztul, M. S. Mukhtar, , J. A. Bibb

This study establishes mouse models of Cdk5-driven Medullary Thyroid Carcinoma (MTC) that recapitulate human tumor aggressiveness and identifies metabolic pathway perturbations as critical for aggressive growth.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology

Genetic Impairment of Succinate Metabolism Disrupts Bioenergetic Sensing in Adrenal Neuroendocrine Cancer

P. Gupta, K. Strange, R. Telange, A. Guo, H. Hatch, A. Sobh, J. Elie, A. M. Carter, J. Totenhagen, C. Tan, Y. A. Sonawane, J. Neuzil, A. Natarajan, A. J. Ovens, J. S. Oakhill, , J. A. Bibb

This paper shows that loss of SDHB in adrenal neuroendocrine cancer disrupts bioenergetic sensing through Cdk5 activation, leading to tumor progression, and that Cdk5 inhibition can reverse this process.

bioRxiv · Jan 9, 2022Cancer Biology

P2X4 Purinergic Receptors as a Therapeutic Target in Aggressive Prostate Cancer

J. P. Maynard, J. Lu, I. Vidal, J. Hicks, L. Mummert, T. Ali, R. Kempski, A. M. Carter, R. Sosa, L. B. Peiffer, C. E. Joshu, T. L. Lotan, A. M. De Marzo, K. S. Sfanos

This study identifies P2X4 purinergic receptors as a driver of aggressive prostate cancer and a potential therapeutic target through in vitro and in vivo experiments.

bioRxiv · Jun 4, 2021Cancer Biology

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors

A. M. Carter, N. Kumar, B. Herring, C. Tan, R. Guenter, R. Telange, W. Howse, F. Viol, C. Graham, T. R. McCaw, h. Bickerton, F. Gillardon, E. A. Woltering, J. Totenhagen, R. Banerjee, , J. Bibb

This paper develops a mouse model of PanNETs driven by Cdk5 and shows its relevance to human tumors, supporting Cdk5 as a therapeutic target.

bioRxiv · May 25, 2021Cancer Biology

Novel anti-somatostatin receptor 2 antibody-drug conjugate for neuroendocrine cancer therapy

Y. Si, S. Kim, R. Guenter, J. Ou, Y. Lu, K. Chen, J. Zhang, J. Whitt, A. M. Carter, J. A. Bibb, J. M. Markert, R. Jaskula-Sztul, L. Zhou, H. Chen, X. Liu

This study develops an anti-somatostatin receptor 2 antibody-drug conjugate (ADC) that effectively targets and kills neuroendocrine tumors with minimal toxicity.

bioRxiv · Nov 18, 2019 · PreprintBioengineering

Phosphoprotein-based Biomarkers as Predictors for Cancer Therapy

A. M. Carter, C. Tan, K. Pozo, R. Telange, R. Molinaro, A. Guo, E. De Rosa, J. O. Martinez, S. Zhang, N. Kumar, M. Takahashi, T. Wiederhold, H. K. Ghayee, S. C. Oltmann, K. Pacak, , J. A. Bibb

The paper identifies phosphoprotein biomarkers for Cdk5 activity in neuroendocrine tumors and shows their predictive value for anti-Cdk5 therapy.

bioRxiv · Jun 20, 2019Cancer Biology